Gebundenes Buch

RAS: Past, Present, and Future

Versandkostenfrei!
Versandfertig in 6-10 Tagen
105,99 €
inkl. MwSt.
Weitere Ausgaben:
PAYBACK Punkte
53 °P sammeln!
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically tar...